目的 探讨参麦注射液对晚期乳腺癌患者放化疗过程中肝肾毒性及白细胞异常的抑制研究.方法 研究对象选取收治的58例女性Ⅳ期乳腺癌患者,随机分成2组,每组29例,均予5-羟色胺3(5-hydroxytryptamine,5-HT3)受体拮抗剂和白细胞生长激素等常规疗法,对照组予吉西他滨联合顺铂化疗方案,28d为1个周期,研究组在上述基础上同时予参麦注射液静滴,每周期间隔15d,均治疗3个周期.检测治疗前后外周血T淋巴细胞亚群、细胞因子水平和肝肾功能,评估生活质量,比较临床疗效.结果 与治疗前比较,对照组CD3+、CD4+及CD4+/CD8+降低(P<0.05),研究组CD3+、CD4+及CD4+/CD8+升高(P<0.05),CD8+降低(P<0.05),2组γ-干扰素(IFN-γ)、白介素-2(IL-2)及肿瘤坏死因子-α(TNF-α)水平升高(P<0.05)白介素-6(IL-6)、水平降低(P<0.05),卡氏功能状态评分(Karnofsky Performance Score)升高(P<0.05),乳腺癌生命质量测定量表(Functional Assessment of Cancer Therapy-Breast,FACT-B)评分降低(P<0.05),丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、血尿素氮(BUN)水平升高(P<0.05),白细胞计数(WBC)、肌酐清除率(Ccr)降低(P<0.05);与对照组比较,研究组CD3+、CD4+及CD4+/CD8+较高(P<0.05),CD8+较低(P<0.05),IFN-γ、IL-2及TNF-α水平较高(P<0.05),IL-6水平较低(P<0.05),总有效率较高(P<0.05),ALT、AST、BUN水平较低(P<0.05),CCr、WBC计数较高(P<0.05).治疗后,研究组临床疗效显著高于对照组(Z=-2.142,P=0.032<0.05).结论 参麦注射液辅助晚期乳腺癌放化疗,可增强放化疗疗效,有效抑制肝肾损伤和白细胞异常.
Shenmai injection for inhibition of hepatic and renal toxicity and leukocyte disorder during chemoradiotherapy in advanced breast cancer
Objective To investigate the Shenmai injection for the inhibition of hepatic and renal toxicity and leukocyte disorder during chemoradiotherapy in the women with advanced breast cancer. Methods 58 cases of female breast cancer patients with stage Ⅳ were selected and randomly divided into 2 groups, 29 cases of each group, and patients were treated with 5-hydroxytryptamine (5-HT3) receptor antagonists and white blood cell growth hormone and other conventional therapy, the control group received gemcitabine plus cisplatin chemotherapy, 28d for 1 cycles, the treatment group received more with Shenmai injection, interval was 15d, 2 groups were treated for 3 cycles. Levels of peripheral blood T lymphocyte subsets, cytokine levels and liver and kidney function, quality of life and clinical efficacy were compared. Results Compared with before treatment, levels of CD3+, CD4+ and CD4+/CD8+ in control group decreased (P<0.05), levels of CD3+, CD4+ and CD4+/CD8+ in treatment group increased (P<0.05), levels of CD8+ decreased(P<0.05), levels of IFN-γ, IL-2 and TNF-α increased(P<0.05), levels of IL-6 decreased(P<0.05), scores of KPS increased(P<0.05), scores of FACT-B decreased(P<0.05), levels of ALT, AST, BUN increased(P<0.05), and levels of CCr, WBC counts decreased(P<0.05), and compared with the control group, levels of CD3+ , CD4+ and CD4+/CD8+ in the treatment group were higher(P<0.05), levels of CD8+ were lower(P<0.05), levels of IFN-γ, IL-2 and TNF-α were higher(P<0.05), levels of IL-6 were lower(P<0.05), and the total efficiency was higher(P<0.05), levels of ALT, AST, BUN were lower (P<0.05), and levels of CCr, WBC counts were higher (P<0.05). After treatment, the efficacy of treatment group was higher than that of control group(Z=-2.142,P=0.032<0.05). Conclusion Shenmai injection can improve the efficacy of radiotherapy and chemotherapy in patients with advanced breast cancer, and it can effectively inhibit the liver and kidney damage and leukocyte disorder.
advanced breast cancerradiotherapy and chemotherapyShenmaihepatic and renal toxicityleukocyte disorder
NETL
NSTL
万方数据
维普
